
The US Supreme Court on Monday put an end to Oracle’s challenge to how the Pentagon awarded the government’s now-canceled $10 billion JEDI cloud computing contract.
The justices declined to hear Oracle’s appeal of a lower court ruling that found that the Austin, Texas-based business software maker was not harmed by any errors made by the Pentagon in awarding the contract because the company would not have qualified for it in the first place.
The US Defense Department awarded the sole-source cloud computing procurement contract to Microsoft in 2019, but scrapped that deal in July, announcing a new contract that is expected to include Amazon, which also had been excluded from the prior one.
Oracle wanted the justices to hear the appeal despite the fact that the JEDI contract had been canceled because it said the flaws in that contract could recur as the government screens bidders for a new one.
The now-canceled Joint Enterprise Defense Infrastructure Cloud (JEDI) contract was part of a broader digital modernization of the Pentagon aimed at making it more technologically agile.
Oracle sued in 2018 to protest the structure of the procurement and certain Pentagon employees’ conflicts of interest involving Amazon, which ultimately lost the JEDI award to Microsoft.
The Washington-based US Court of Appeals for the Federal Circuit, which hears appeals involving government contracts, ruled against Oracle last year, saying that the company would not have had a substantial chance of securing the contract.
Like Oracle, Amazon had filed suit protesting the JEDI sole-source deal, arguing that then-President Donald Trump exerted improper pressure on military officials to steer the contract away from Amazon.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas